CURRENT OPINION IN PHARMACOLOGY

Scope & Guideline

Transforming Ideas into Impactful Solutions

Introduction

Welcome to the CURRENT OPINION IN PHARMACOLOGY information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of CURRENT OPINION IN PHARMACOLOGY, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1471-4892
PublisherELSEVIER SCI LTD
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 2001 to 2024
AbbreviationCURR OPIN PHARMACOL / Curr. Opin. Pharmacol.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address125 London Wall, London EC2Y 5AS, ENGLAND

Aims and Scopes

CURRENT OPINION IN PHARMACOLOGY serves as a platform for the dissemination of cutting-edge research and reviews in the field of pharmacology, emphasizing therapeutic innovations, mechanistic insights, and translational applications. The journal aims to bridge the gap between basic research and clinical practice, providing insights into emerging therapies and pharmacological strategies.
  1. Therapeutic Innovations:
    The journal focuses on novel therapeutic strategies and advancements in drug development across various medical fields, including oncology, neurology, and pain management.
  2. Mechanistic Insights:
    Emphasizing the understanding of biochemical and molecular mechanisms underlying drug action and disease pathology, the journal publishes studies that elucidate the pharmacodynamics and pharmacokinetics of new and existing drugs.
  3. Translational Research:
    CURRENT OPINION IN PHARMACOLOGY highlights the translation of laboratory findings into clinical applications, showcasing studies that connect preclinical research with potential therapeutic outcomes.
  4. Disease-Specific Pharmacology:
    The journal addresses pharmacological approaches tailored to specific diseases, including autoimmune disorders, metabolic syndromes, and neurodegenerative conditions.
  5. Interdisciplinary Approaches:
    Encouraging collaboration across disciplines, the journal publishes research that integrates pharmacology with fields such as genetics, immunology, and systems biology to develop comprehensive therapeutic strategies.
CURRENT OPINION IN PHARMACOLOGY has identified several trending and emerging themes that reflect the journal's responsiveness to contemporary challenges in pharmacology and therapeutics. These themes highlight areas of increasing research focus and potential for future developments.
  1. Pain Management Innovations:
    Recent publications demonstrate a growing emphasis on innovative pain management strategies, including the exploration of novel targets such as TRP channels and the endocannabinoid system, as well as biased signaling in analgesics.
  2. Targeted Therapies in Cancer:
    There is a surge in research focusing on targeted therapies for cancer treatment, particularly those that leverage advancements in understanding DNA damage repair and tumor microenvironment interactions.
  3. Neuropharmacology Advances:
    Emerging studies on neuropharmacology, particularly regarding neurodegenerative diseases and mental health, reflect a trend towards developing therapies that address complex neurological pathways.
  4. Personalized Medicine and Pharmacogenomics:
    The journal is increasingly featuring articles on personalized medicine approaches, highlighting the importance of pharmacogenomics in tailoring treatments to individual patient profiles.
  5. Integration of AI and Computational Methods:
    The incorporation of artificial intelligence and computational modeling in drug discovery and pharmacology is gaining traction, signifying a trend towards data-driven approaches in therapeutic development.

Declining or Waning

As the field of pharmacology evolves, certain themes and research areas have shown a decline in prominence within CURRENT OPINION IN PHARMACOLOGY. This section highlights those aspects that are becoming less common in recent publications.
  1. Traditional Pharmacotherapy:
    There is a noticeable decline in papers focused on traditional pharmacotherapy approaches, as the field shifts towards more innovative and personalized medicine strategies that incorporate genetic and molecular insights.
  2. General Reviews without Novel Insights:
    The journal has seen a reduction in general review articles that do not contribute new insights or perspectives, with a preference for publications that offer novel findings or advanced methodologies.
  3. Single-Drug Focus Studies:
    Research focusing solely on the efficacy of single drugs without considering combination therapies or multidisciplinary approaches appears to be less frequent, reflecting a broader trend towards integrative treatment strategies.
  4. Overemphasis on Mechanistic Studies:
    While mechanistic studies remain important, there is a declining interest in purely mechanistic explorations without translational implications, as researchers and clinicians increasingly seek studies with direct clinical relevance.

Similar Journals

DRUG DEVELOPMENT RESEARCH

Empowering researchers with cutting-edge findings in drug research.
Publisher: WILEYISSN: 0272-4391Frequency: 8 issues/year

DRUG DEVELOPMENT RESEARCH is a premier interdisciplinary journal published by Wiley, focusing on the latest advancements in drug discovery, pharmacology, and toxicology. With an ISSN of 0272-4391 and an E-ISSN of 1098-2299, this esteemed publication has been a cornerstone in the field since its inception in 1981 and continues to provide cutting-edge research until 2024. Its rigorous peer-review process and strategic placement in Q2 of the Drug Discovery category, as well as ranking #60 out of 157 in Scopus, underscore the journal's relevance and influence, boasting a respectable 62nd percentile ranking. While the journal does not currently offer open access, it remains a vital resource for researchers, professionals, and students seeking to expand their knowledge on the processes of drug development, identifying new therapeutic targets, and assessing the efficacy and safety of novel compounds. Situated in Hoboken, NJ, this journal stands at the forefront of pharmaceutical innovation, making significant contributions to the advancement of medical science.

Recent Advances in Inflammation & Allergy Drug Discovery

Exploring breakthroughs in inflammation and allergy science.
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 2772-2708Frequency: 2 issues/year

Recent Advances in Inflammation & Allergy Drug Discovery, published by Bentham Science Publishers Ltd, is an esteemed open-access journal dedicated to the dynamic fields of drug discovery, immunology, and allergy. Since its inception in 2021, this journal has emerged as a crucial platform for disseminating groundbreaking research and innovative methodologies that drive forward our understanding of inflammatory processes and allergic diseases. With an ISSN of 2772-2708 and an E-ISSN of 2772-2716, it is currently indexed in various categories, boasting a Q3 ranking in Drug Discovery and Immunology & Allergy, and a Q1 ranking in Medicine (miscellaneous) for 2022. Operating from the United Arab Emirates, the journal aims to bridge the gap between laboratory research and clinical application, offering a comprehensive collection of articles that are accessible to a broad audience. Through its commitment to open access, it ensures that critical findings are widely available, fostering collaboration and innovation among researchers, practitioners, and students alike. Join the scholarly community engaged in this vital area of research and contribute to the ongoing advancements in inflammation and allergy therapeutics.

Expert Review of Clinical Pharmacology

Advancing clinical care through expert pharmacological insights.
Publisher: TAYLOR & FRANCIS LTDISSN: 1751-2433Frequency: 12 issues/year

Expert Review of Clinical Pharmacology, published by TAYLOR & FRANCIS LTD, is a leading peer-reviewed journal dedicated to the field of clinical pharmacology, with a strong focus on the development and application of pharmacological therapies in patient care. Boasting an impressive impact, the journal ranks in the first quartile across multiple categories including Medicine (miscellaneous), Pharmacology (medical), and Pharmacology, Toxicology and Pharmaceutics (miscellaneous), reflecting its influential position within the scientific community. With a Scopus ranking of #6 in General Pharmacology, Toxicology and Pharmaceutics, the journal also achieves a commendable 93rd percentile, further emphasizing its importance as a resource for researchers and clinicians alike. As it continues to publish innovative reviews and research articles from 2008 until 2024, the Expert Review of Clinical Pharmacology plays an essential role in advancing knowledge, improving clinical practice, and fostering collaboration among experts in pharmacology, thereby driving forward the field's evolution towards better patient outcomes.

INVESTIGATIONAL NEW DRUGS

Pioneering Innovations in Drug Development
Publisher: SPRINGERISSN: 0167-6997Frequency: 6 issues/year

INVESTIGATIONAL NEW DRUGS is a prestigious journal published by SPRINGER, dedicated to advancing research in the fields of pharmacology and oncology. With its origins dating back to 1983, the journal continues to play a critical role in disseminating groundbreaking studies and innovative methodologies related to drug development and therapeutic strategies. It holds an impressive impact factor among leading academic publications, ranking in the top quartiles (Q1 and Q2) of its respective categories, evidenced by Scopus rankings of #43/272 in Medical Pharmacology and #88/404 in Medical Oncology. While it offers traditional subscription-based access, it remains an essential resource for researchers, professionals, and students eager to stay abreast of significant advancements in drug research. Through rigorous peer review and comprehensive coverage, INVESTIGATIONAL NEW DRUGS aims to foster the development of effective new therapies and enhance our understanding of pharmacological interventions in oncology.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Transforming Knowledge into Therapeutic Solutions
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Journal of Pharmacological Sciences

Advancing pharmacological research for a healthier tomorrow.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

ACTA PHARMACOLOGICA SINICA

Connecting Global Minds in Pharmacology
Publisher: NATURE PUBL GROUPISSN: 1671-4083Frequency: 12 issues/year

ACTA PHARMACOLOGICA SINICA is a premier journal in the field of pharmacology, published by the esteemed Nature Publishing Group. With a strong history since its inception in 1980, this journal is recognized for its impactful contributions to the fields of medicine and pharmacology, consistently securing a Q1 ranking in multiple relevant categories, including Pharmacology (Medical). Drawing on a robust international readership, it ranks impressively at #8 out of 272 in the specialty of Medical Pharmacology, placing it in the top 97th percentile according to Scopus data. Although currently not an open-access publication, ACTA PHARMACOLOGICA SINICA remains a vital resource for researchers, professionals, and students seeking to advance their understanding of pharmacological sciences. Its commitment to disseminating high-quality research underscores its significance in fostering innovation and exploration in the medical landscape.

Annual Review of Pharmacology and Toxicology

Leading the conversation in drug safety and efficacy.
Publisher: ANNUAL REVIEWSISSN: 0362-1642Frequency: 1 issue/year

Annual Review of Pharmacology and Toxicology is a leading journal published by ANNUAL REVIEWS, renowned for its comprehensive and critical reviews of the fields of pharmacology and toxicology. With an esteemed history spanning from 1965 to the present and an impressive Q1 ranking in both categories, this journal stands at the forefront of scholarly communication in pharmacological sciences. Researchers are encouraged to submit cutting-edge studies that advance knowledge and innovation in drug development, safety assessments, and therapeutic practices. Although this journal does not currently offer Open Access options, it remains a vital resource for professionals and students who seek to stay updated with the latest high-impact research findings. The journal is indexed in Scopus, boasting remarkable rankings, including Rank #1 in Toxicology and Rank #4 in Pharmacology, reflecting its pivotal role in shaping the discourse in these dynamic fields.

JOURNAL OF PHARMACY AND PHARMACOLOGY

Pioneering research for transformative healthcare solutions.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.

INDIAN JOURNAL OF PHARMACOLOGY

Innovating drug action insights to enhance therapeutic practices.
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 0253-7613Frequency: 6 issues/year

INDIAN JOURNAL OF PHARMACOLOGY, published by Wolters Kluwer Medknow Publications, is a premier platform dedicated to advancing the field of pharmacology and its related disciplines. With a rich history since its inception in 1978, this journal aims to disseminate high-quality research findings, reviews, and clinical studies that contribute to the global understanding of drug action and therapeutic practices. As a valuable resource for researchers, professionals, and students alike, it operates within the Q3 quartile of the Pharmacology category, positioning itself as an influential contributor in the realm of medical pharmacology. The journal is committed to publishing rigorous scientific inquiry, fostering innovation, and bridging gaps between laboratory research and clinical application. Readers can access its wide-ranging articles to stay informed about the latest advancements in the field, reflecting its crucial role in shaping future pharmacological research and practice.